- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00129519
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
July 14, 2010 updated by: Graceway Pharmaceuticals, LLC
Open-label Study to Evaluate the Use of Imiquimod 5% Cream for Reducing Postsurgical Recurrence or Persistence of Basal Cell Carcinoma Following Excision by Curettage
The primary objective of this study is to assess whether basal cell carcinoma (BCC) lesions surgically treated with curettage, followed by imiquimod 5% cream as postsurgical adjuvant therapy, will have an improved cure rate over the ED/C historical norm of approximately 70% at 1-year posttreatment follow-up.
A secondary objective is to assess cosmetic outcome.
Study Overview
Detailed Description
This was an open-label, phase IIIb, multicenter, single arm, historical-controlled study.
Biopsy-confirmed BCC lesions (1 per subject) were excised by curettage, with no electrodessication.
Approximately 1 week later, treatment with imiquimod 5% cream was initiated.
Imiquimod was applied to the target BCC once daily, 5 times per week (5x/week) for up to 6 weeks.
Rest periods were allowed as needed.
Subjects reported to the study center at treatment weeks 1, 2, and 6, and posttreatment at weeks 12, 26, and 52.
At treatment week 6 and all posttreatment visits, the investigator clinically assessed the target site for tumor clearance and cosmetic outcome.
A template made at initiation and created from clear plastic overlay aided in locating the target tumor site.
If the investigator identified a lesion that had occurred or recurred at the target site, the subject was discontinued from the study and counted as a recurrence/persistence (R/P).
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Grass Valley, California, United States, 95945
-
Loma Linda, California, United States, 92354
-
-
New York
-
New York, New York, United States, 10016
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Basal cell carcinoma
Exclusion Criteria:
- Psoriasis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Imiquimod cream
Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
|
Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with recurrence
Time Frame: 1 year posttreatment
|
Primary variable was the proportion of subjects with recurrence/persistence (R/P)of BCC at 1 year posttreatment
|
1 year posttreatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cosmetic outcome of the target lesion
Time Frame: 1 year posttreatment
|
The cosmetic outcome of the target lesion at 1 year posttreatment was the secondary efficacy measurement.
The investigator judged cosmetic outcome by using a visual analog scale (VAS) to assess the parameters of hypo- and hyperpigmentation,roughness, scarring, and overall skin health and appearance.
|
1 year posttreatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Primary Completion (Actual)
January 1, 2006
Study Completion (Actual)
January 1, 2006
Study Registration Dates
First Submitted
August 11, 2005
First Submitted That Met QC Criteria
August 11, 2005
First Posted (Estimate)
August 12, 2005
Study Record Updates
Last Update Posted (Estimate)
July 16, 2010
Last Update Submitted That Met QC Criteria
July 14, 2010
Last Verified
July 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neoplasms, Basal Cell
- Carcinoma
- Recurrence
- Carcinoma, Basal Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Adjuvants, Immunologic
- Interferon Inducers
- Imiquimod
Other Study ID Numbers
- 1491-IMIQ
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
Christopher ZacharyRecruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Graceway Pharmaceuticals, LLCCompletedSuperficial Basal Cell CarcinomaAustralia, New Zealand
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
Biofrontera Bioscience GmbHAccovion GmbHCompletedBasal Cell Carcinoma (BCC)Germany
-
Berg, LLCCompletedSuperficial Basal Cell CarcinomaUnited States
-
PeplinCompletedSuperficial Basal Cell CarcinomaAustralia
Clinical Trials on Imiquimod 5% cream
-
Graceway Pharmaceuticals, LLCCompletedActinic KeratosisUnited States
-
Graceway Pharmaceuticals, LLCCompletedSuperficial Basal Cell CarcinomaAustralia, New Zealand
-
Graceway Pharmaceuticals, LLCCompletedKeratosisUnited States
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
St. Justine's HospitalGraceway Pharmaceuticals, LLCCompletedHemangioma, CapillaryCanada
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
Medical University InnsbruckNot yet recruitingAnogenital Human Papillomavirus Infection | Condyloma AnalAustria
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
VA Office of Research and DevelopmentNot yet recruiting